

Vivienne Kahlmann - NRS Travel Grant – WASOG 2024, Agra, India

The WASOG 2024 conference (World Association for Sarcoidosis and Other Granulomatous Disorders) took place in Agra, India, from November 14-17. During this international event, the latest advancements in sarcoidosis and other interstitial lung diseases were presented.

During the conference, I had the opportunity to present the results of the PREDMETH trial, a randomized controlled study comparing methotrexate and prednisone as first-line treatments for pulmonary sarcoidosis. Our study found that, after 24 weeks of treatment, methotrexate is non-inferior to prednisone, as assessed by changes in FVC. The results generated significant interest and led to an engaging discussion on their clinical implications.

Beyond pulmonary sarcoidosis, the conference sessions on extrapulmonary manifestations, particularly cardiac sarcoidosis, introduced novel concepts that are highly relevant to my research.

I would like to thank the NRS for supporting my participation in the WASOG conference. Attending the event was a valuable opportunity to learn about the latest innovations, expand my network, and foster meaningful collaborations with fellow researchers.